Kidney-type Glutaminase (GLS1) is a Biomarker for Pathologic Diagnosis and Prognosis of Hepatocellular Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Apr 7

PMID 25844758

Citations 61

Authors

Decai Yu

XianBiao Shi

Gang Meng

Jun Chen

Chen Yan

Yong Jiang

Jiwu Wei

Yitao Ding

Affiliations

Soon will be listed here.

Abstract

The lack of sensitive and specific biomarkers hinders pathological diagnosis and prognosis for hepatocellular carcinoma (HCC). Since glutaminolysis plays a crucial role in carcinogenesis and progression, we sought to determine if the expression of kidney-type and liver-type glutaminases (GLS1 and GLS2) were informative for pathological diagnosis and prognosis of HCC. We compared the expression of GLS1 and GLS2 in a large set of clinical samples including HCC, normal liver, and other liver diseases. We found that GLS1 was highly expressed in HCC; whereas, expression of GLS2 was mainly confined to non-tumor hepatocytes. The sensitivity and specificity of GLS1 for HCC were 96.51% and 75.21%, respectively. A metabolic switch from GLS2 to GLS1 was observed in a series of tissues representing progressive pathologic states mimicking HCC oncogenic transformation, including normal liver, fibrotic liver, dysplasia nodule, and HCC. We found that high expression of GLS1 and low expression of GLS2 in HCC correlated with survival time of HCC patients. Expression of GLS1 and GLS2 were independent indexes for survival time; however, prognosis was predominantly determined by the level of GLS1 expression. These findings indicate that GLS1 expression is a sensitive and specific biomarker for pathological diagnosis and prognosis of HCC.

Citing Articles

Interactions between the metabolic reprogramming of liver cancer and tumor microenvironment.

Yang H, Li J, Niu Y, Zhou T, Zhang P, Liu Y Front Immunol. 2025; 16:1494788.

PMID: 40028341 PMC: 11868052. DOI: 10.3389/fimmu.2025.1494788.

Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications.

Park S, Hall M Exp Mol Med. 2025; .

PMID: 40025169 DOI: 10.1038/s12276-025-01415-2.

Associations between circulating amino acids and metabolic dysfunction-associated steatotic liver disease in individuals living with severe obesity.

Maltais-Payette I, Bourgault J, Gauthier M, Biertho L, Marceau S, Julien F Physiol Rep. 2025; 13(3):e70171.

PMID: 39868884 PMC: 11770886. DOI: 10.14814/phy2.70171.

Metabolic checkpoints in glioblastomas: targets for new therapies and non-invasive detection.

Li W, Wang Z, Chen S, Zuo M, Xiang Y, Yuan Y Front Oncol. 2024; 14:1462424.

PMID: 39678512 PMC: 11638224. DOI: 10.3389/fonc.2024.1462424.

Glutaminase - A potential target for cancer treatment.

Anthony J, Varalakshmi S, Sekar A, Devarajan N, Janakiraman B, Peramaiyan R Biomedicine (Taipei). 2024; 14(2):29-37.

PMID: 38939098 PMC: 11204126. DOI: 10.37796/2211-8039.1445.

References

Wang J, Erickson J, Fuji R, Ramachandran S, Gao P, Dinavahi R . Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010; 18(3):207-19. PMC: 3078749. DOI: 10.1016/j.ccr.2010.08.009. View

Matsuno T . Bioenergetics of tumor cells: glutamine metabolism in tumor cell mitochondria. Int J Biochem. 1987; 19(4):303-7. DOI: 10.1016/0020-711x(87)90002-4. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Cassago A, Ferreira A, Ferreira I, Fornezari C, Gomes E, Greene K . Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci U S A. 2012; 109(4):1092-7. PMC: 3268272. DOI: 10.1073/pnas.1112495109. View

Yuneva M, Fan T, Allen T, Higashi R, Ferraris D, Tsukamoto T . The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012; 15(2):157-70. PMC: 3282107. DOI: 10.1016/j.cmet.2011.12.015. View

Tremosini S, Forner A, Boix L, Vilana R, Bianchi L, Reig M . Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut. 2012; 61(10):1481-7. DOI: 10.1136/gutjnl-2011-301862. View

Shukla K, Ferraris D, Thomas A, Stathis M, Duvall B, Delahanty G . Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem. 2012; 55(23):10551-63. PMC: 3539823. DOI: 10.1021/jm301191p. View

Zhao Y, Butler E, Tan M . Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013; 4:e532. PMC: 3613838. DOI: 10.1038/cddis.2013.60. View

Mates J, Segura J, Martin-Rufian M, Campos-Sandoval J, Alonso F, Marquez J . Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med. 2012; 13(4):514-34. DOI: 10.2174/1566524011313040005. View

10.

Meng G, Xia M, Xu C, Yuan D, Schnurr M, Wei J . Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation. Int J Cancer. 2013; 134(8):1958-71. DOI: 10.1002/ijc.28416. View

11.

Martin-Rufian M, Nascimento-Gomes R, Higuero A, Crisma A, Campos-Sandoval J, Gomez-Garcia M . Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. J Mol Med (Berl). 2013; 92(3):277-90. PMC: 4327995. DOI: 10.1007/s00109-013-1105-2. View

12.

Gross M, Demo S, Dennison J, Chen L, Chernov-Rogan T, Goyal B . Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014; 13(4):890-901. DOI: 10.1158/1535-7163.MCT-13-0870. View

13.

Liu J, Zhang C, Lin M, Zhu W, Liang Y, Hong X . Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget. 2014; 5(9):2635-47. PMC: 4058033. DOI: 10.18632/oncotarget.1862. View

14.

Aledo J, Olalla L, Marquez J . Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm Genome. 2000; 11(12):1107-10. DOI: 10.1007/s003350010190. View

15.

Turner A, McGivan J . Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas. Biochem J. 2002; 370(Pt 2):403-8. PMC: 1223172. DOI: 10.1042/BJ20021360. View

16.

Li Y, Tian B, Yang J, Zhao L, Wu X, Ye S . Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol. 2004; 130(8):460-8. DOI: 10.1007/s00432-004-0564-9. View

17.

Williams A, Piris J, Wyllie A . ras p21 expression in the progression of breast cancer. Hum Pathol. 1988; 19(9):1115. DOI: 10.1016/s0046-8177(88)80096-0. View

18.

Matsuno T, Hirai H . Glutamine synthetase and glutaminase activities in various hepatoma cells. Biochem Int. 1989; 19(2):219-25. View

19.

Curthoys N, Watford M . Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995; 15:133-59. DOI: 10.1146/annurev.nu.15.070195.001025. View

20.

Yamanoi A, Soda Y, Yamaguchi M, Yu L, Nagasue N . Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma. Surgery. 1997; 122(3):571-7. DOI: 10.1016/s0039-6060(97)90130-6. View